Clinical trials: Immunoglobulin
HIV
A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults
Background: HIV is a serious disease with no cure or vaccine to prevent it. Using antibodies could be a way to prevent HIV infection. Antibodies are made by the human body to fight germs.
- Trial name
- VRC 611 (NCT04408963)
- Testing
- VRC-HIVMAB0102-00-AB
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer
CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with anti-PD1 antibody plus dihydroartemisinin as neoadjuvant or conversion therapy for pMMR/MSS locally advanced and metastatic…
- Trial name
- NCT07801352
- Testing
- Capecitabine, Oxaliplatin, Dihydroartemisinin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Changzheng Hospital
Multiple Sclerosis
REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients
The purpose of the study is to determine if Interferon-alfa is effective and safe in multiple sclerosis patients who developed neutralizing antibodies for Interferon-beta.
- Trial name
- REPAIR (NCT01171209)
- Testing
- Interferon-beta and human leukocyte Interferon-α
- Volunteers
- 10 people
- Sponsor
- Melinda Magyari
Solid Tumor
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
- Trial name
- NCT02216409
- Testing
- Hu5F9-G4
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- Gilead Sciences
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Rituximab is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of patients with granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis.
- Trial name
- RAVELOS (NCT01586858)
- Testing
- Observational
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 67 people
- Sponsor
- Johns Hopkins University
Gallbladder Cancer
Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC
The TOPAZ-1 study compared the advantages and disadvantages of immune checkpoint inhibitor anti-PD-L1 antibody combined with Gem/Cis chemotherapy (Gemcitabine and Cisplatin) and Gem/Cis chemotherapy alone in first-line treatment…
- Trial name
- NCT06013943
- Testing
- Envafolimab+Gemox
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Primary Immune Deficiency Disorder
Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)
The objective of this study is to assess the long-term safety, tolerability, and efficacy of IgPro20 in subjects with primary immunodeficiency (PID) as a follow-up to the pivotal study ZLB06_002CR (NCT01199705).
- Trial name
- NCT01458171
- Testing
- Immune globulin subcutaneous (Human)
- Where
- 9 sites in Japan
- Volunteers
- 23 people
- Sponsor
- CSL Behring
Cancer
A Trial of PDL192 in Subjects With Advanced Solid Tumors
This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.
- Trial name
- NCT00738764
- Testing
- PDL192
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Abbott
Systemic Lupus Erythematosus
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
This study is a randomized, controlled, phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with systemic lupus erythematosus.
- Trial name
- NCT06857214
- Testing
- GNC-038, Belimumab
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Relapsed/Refractory Non-Hodgkin's Lymphoma
Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL
Lymphoma is one of the fastest growing malignancies in the world, with an annual incidence rate of about 4%. Non-Hodgkin's lymphoma (NHL) is highly heterogeneous and can be broadly divided into two major categories, B-cell…
- Trial name
- NCT04134247
- Testing
- PD-1 combined with chemotherapy, chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shandong Provincial Hospital
Idiopathic Thrombocytopenic Purpura
IGIV Study for Chronic ITP Patients Ages 3-70
Idiopathic (immune) thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by platelet destruction and thrombocytopenia (peripheral blood platelet count < 150 x 10^9/L).
- Trial name
- NCT00511147
- Testing
- IGIV3I Grifols 10%
- Where
- 45 sites in United States, Canada and 2 more
- Volunteers
- 64 people
- Sponsor
- Grifols Biologicals, LLC
Hepatocellular Carcinoma
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) who…
- Trial name
- NCT06361758
- Testing
- Cadonilimab+Lenvatinib
- Where
- 3 sites in China
- Sponsor
- Shanghai Zhongshan Hospital
Atopic Dermatitis
Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life
This experimental non-randomized clinical study is aimed at comparing the efficacy and safety assessment of the proposed topical therapy algorithms with the use of topical calcineurin inhibitors in reducing the severity of atopic…
- Trial name
- NCT04900948
- Testing
- Pimecrolimus cream 1%, cream 0.1% methylprednisolone aceponate
- Where
- Russia
- Volunteers
- 108 people
- Sponsor
- National Medical Research Center for Children's Health, Russian Federation
Advanced Solid Tumor
A Study of YL201 in Patients With Advanced Solid Tumors
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States.
- Trial name
- NCT05434234
- Testing
- YL201, YL201 and atezolizumab
- Where
- 45 sites in United States, Canada and 4 more
- Volunteers
- 312 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Cervical Cancer
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.
- Trial name
- NCT05838521
- Testing
- Sacituzumab govitecan
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Resectable Non-small Cell Lung Cancer
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
- Trial name
- NCT05247684
- Testing
- AK112, Carboplatin, Cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Advanced Cancer
A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
The purpose of this study is to evaluate the safety and tolerability of JNJ-61610588 in participants with advanced cancer in order to determine a recommended Phase 2 dose (RP2D) for further evaluation in specific tumor types.
- Trial name
- NCT02671955
- Testing
- JNJ-61610588
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
mCRC, HER2
MA-CRC-II-016 SHR-1811
A randomized, controlled, multicenter clinical study of SHR-A1811 combined with bevacizumab for the second-line treatment of metastatic colorectal cancer
- Conditions
- mCRC, HER2, Targeted Therapy, Antibody-drug Conjugates
- Trial name
- NCT07355764
- Testing
- SHR-A1811 & Bevacizumab injection, Chemotherapeutic Combinations
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Cholangiocarcinoma
Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations
The purpose of this study is to determine the rate of progression free survival of patients with inoperable cholangiocarcinoma 6 months after enrollment in the study.
- Trial name
- GOC-B-P (NCT01206049)
- Testing
- Gemcitabine, Oxaliplatin, Capecitabine
- Where
- Denmark
- Volunteers
- 88 people
- Sponsor
- Vejle Hospital
Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC)
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
The goal of this clinical trial is to evaluate CLBR001 and ABBV-461 as a treatment for patients with locally advanced or metastatic breast cancer.
- Conditions
- Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC), Malignant Neoplasm of Breast, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT06878248
- Testing
- Two Component Product CLBR001 + ABBV-461
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Calibr, a division of Scripps Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.